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Background: Ankylosing spondylitis (AS) is an inflammatory disease with documented elevated cardiovascular (CV)
risk due to systemic inflammation and a higher prevalence of CV risk factors. CV risk management (CV-RM) could be
an effective method to reduce CV mortality and morbidity in AS patients. We assessed CV risk and evaluated
guideline adherence according to the Dutch CV-RM guideline.
Methods: This study was conducted with a cohort of consecutive AS patients eligible for treatment with a tumor
necrosis factor (TNF) -α inhibitor. Data from the Dutch National Institute for Public Health and Environment was
used to compare the prevalence of CV risk factors in AS patients with the Dutch background population.
Results: In total, 254 consecutive AS patients were included. The prevalences of hypertension (41% vs 31%) and
smoking (43% vs 27%) were substantially higher in AS patients as compared to the general Dutch background
population. Of 138 AS patients older than 40 years the 10-years CV risk could be calculated. Fifty-one of these 138
patients (37%) had an indication for CV risk treatment. CV risk treatment was initiated in 42 of the 51 (82%), however, in
only 12 of the 51 (24%) patients treatment targets for either hypertension or hypercholesterolemia were reached.
Conclusion: The increased rates of hypertension and smoking illustrate the importance of CV-RM in AS patients.
Although the majority of all AS patients eligible for CV-RM received CV risk medication, CV-RM remains a challenge for
treating physicians, as treatment targets were not achieved in three-quarter of the eligible patients.
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Ankylosing spondylitis (AS) is an autoimmune inflam-
matory disease associated with a decreased overall life
expectancy compared to the general population [1,2].
Studies investigating mortality in AS show that the
most common causes of death are of circulatory origin
[3-5]. This increased cardiovascular (CV) mortality and
morbidity is caused by multiple factors. Chronic inflamma-
tion acts independently or synergistically with traditional
risk factors in the pathogenesis of atherosclerosis [3]. Obvi-
ously traditional CV risk factors, such as hypertension,* Correspondence: m.nurmohamed@reade.nl
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unless otherwise stated.hypercholesterolemia, and smoking remain important and
modifiable contributors. Until now, it is still unclear which
CV risk factors are more prevalent in the AS population
compared to the general population, as studies on this sub-
ject and their results are heterogeneous [4-6].
Early identification and optimal CV risk management
are mandatory to reduce the CV risk in AS patients.
Worldwide, various CV risk management (CV-RM) guide-
lines with different algorithms are available [7,8]. Most of
these algorithms do not include inflammation. The
EULAR CV-RM guideline considers AS to be an import-
ant CV risk factor, but unlike rheumatoid arthritis (RA),
does not suggest modification of CV risk calculation for
this group, as epidemiological evidence supporting an in-
creased CV risk is less evident in AS [9]. In recent years,
however, accumulating evidence for the increased CV riskl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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consider multiplying the derived CV risk estimate by 1.5
or adding 15 years to the actual age of an AS patient when
calculating CV risk for a better CV risk estimate. Regard-
less of the algorithm used, it is currently unknown
whether their implementation in AS patients is successful.
As many aspects on CV risk, its risk factors, and man-
agement are still unclear, we 1) assessed the prevalence
of CV risk factors as compared to the prevalence of these
risk factors in the general Dutch population; 2) estimated
the 10-years CV risk in AS patients according to CV risk
algorithms used in the Dutch, European and American
CV-RM guidelines and 3) investigated whether AS patients
at increased CV risk receive optimal preventive treatment
according to the current Dutch CV-RM guideline in a large
cohort of AS patients with active disease.
Methods
Study population
This cross-sectional study was conducted retrospectively.
The study population consisted of 254 consecutive AS pa-
tients who were recruited from two simultaneously running
observational prospective cohorts at the rheumatology de-
partment of the Jan van Breemen Research Institute |
Reade, Amsterdam from August 2004 till August 2012. All
patients fulfilled the 1984 Modified New York criteria for
AS [13]. TNF-α blocking therapy naïve patients were in-
cluded when they were eligible for TNF-α blocking therapy
according to the Dutch consensus statement on the initi-
ation of TNF-α blocking therapy in AS [14]. Approval was
obtained from the local ethics committee (Ethics Commit-
tee of the Slotervaart Hospital and Reade, Amsterdam, The
Netherlands) and all participating patients gave written in-
formed consent.
Patient characteristics
All participating patients underwent a physical examin-
ation and an interview to record details about disease
history, clinical characteristics and demographics before
start of TNF-α blocking therapy. Special attention was
paid to hypercholesterolemia, hypertension, overweight,
type 2 diabetes mellitus (DM), and smoking. History of
cardiovascular disease (CVD) was assessed, including
coronary heart disease, congestive heart failure, cerebro-
vascular disease and peripheral arterial disease. The use
of cholesterol lowering agents, antihypertensives and
non-steroidal anti-inflammatory drugs (NSAIDs) was
also recorded. Disease activity was measured with the
Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI). Physical examination included height, weight
and blood pressure measurements. Blood pressure was
measured manually according to the standard hospital
procedures. Blood sample measurements (non-fasting)
included standard hematological assessment, C-reactiveprotein (CRP), erythrocyte sedimentation rate (ESR),
creatinine and cholesterol levels. A single laboratory an-
alyzed all blood samples.
General population
Prevalences of CV risk factors in this cohort were com-
pared to data from the general Dutch background popu-
lation from TNS-NIPO [15] or the Dutch National
Institute for public health and environment (RIVM)
[16]. The same definitions for the hypertension, hyper-
cholesterolemia and overweight for the background
population and included AS patients were used. Over-
weight was defined as a BMI ≥25 kg/m2 and obesity as a
BMI ≥30 kg/m2. Hypertension was defined as a systolic
blood pressure (SBP) ≥140 mmHg and/or a diastolic
blood pressure (DBP) ≥90 mmHg and/or the use of anti-
hypertensive drugs. Hypercholesterolemia was defined as
total cholesterol (TC) level of ≥6.5 mmol/L and/or use
of cholesterol lowering drugs.
CV risk assessment
The CV risk stratification methods of the Dutch, European
and American CV-RM guidelines were used to estimate
10-years CV risk [7,8,17]. To adjust for the increased CV
risk in AS patients we also calculated the 10-years CV risk
by adding 15 years to the age of the AS patients in the
Dutch risk stratification method. This is standard practice
in all Dutch patients with RA and/or DM, as the CARRE
study by Van Halm et al. showed that the CV risk of RA
patients equals that of DM patients [17,18].
CV risk management
The Dutch CV-RM guidelines were also applied to in-
vestigate whether AS patients at increased CV risk re-
ceived adequate preventive treatment [18]. The Dutch
CV-RM charts were used, as they are specific for the
Dutch population and assesses the total CV burden in-
stead of CV mortality alone. In the Dutch CV-RM
guidelines, gender, age, smoking status, SBP and the TC/
HDL-C ratio are used to calculate CV risk. Smoking was
defined as currently smoking at least once per week.
Patients for whom no cholesterol levels or blood pres-
sure measurements were available, patients with previ-
ous CVD and patients younger than 40 were excluded,
as the Dutch CV-RM guidelines are not validated for
patients aged below 40 years. We categorized patients
into three groups: (1) patients who had an indication
for preventive treatment but did not receive this; (2)
patients who were inadequately treated as they did not
meet the treatment goals (i.e. a SBP ≤140 mmHg and/
or an low density lipoprotein (LDL) -cholesterol ≤
2.5 mmol/L); (3) patients who were treated adequately
or had no increased CV risk or CV risk factors.
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For data analysis SPSS Version 21.0 (SPSS, Chicago,
Illinois, USA) was used. Values are expressed as mean
± standard deviation (SD), median (interquartile range)Table 1 Patient characteristics N = 254
Demographic
Age, years (median, IQR)
Male (number, percentage)
Disease status
Disease duration, years (median, IQR)
HLA-B27 positive (number, percentage)
C-reactive protein, mg/l (median, IQR)
Erythrocyte sedimentation rate, mm/h (median, IQR)
BASDAI (0–10) (mean, SD)
CV risk factors
Prior CVD (number, percentage)
Myocardial infarction (number)
TIA/CVA (number)
Peripheral arterial disease (number)
Smoking (number, percentage)
Systolic blood pressure, mmHg (mean, SD)
Diastolic blood pressure, mmHg (mean, SD)
Hypertension (SBP≥ 140 and/or DBP≥ 90 and/or antihypertensive drugs) (nu
Hypercholesterolemia (TC≥ 6,5 mmol/L and/or cholesterol lowering drugs) (n
Diabetes type 2 (number, percentage)
Body mass index, kg/m2 (mean, SD)
Overweight (≥25 BMI) (number, percentage)
Kidney function (eGRF Cockcroft Gault) ml/min (mean, SD)
Lipid levels
Total cholesterol (mmol/l) (mean, SD)
Triglycerides (mmol/l) (median, IQR)
HDL cholesterol (mmol/l) (mean, SD)
LDL cholesterol (mmol/l) (mean, SD)
Total cholesterol/HDL-C ratio (mean, SD)
Medication
Statins (number, percentage)







Data is expressed as number (percentage), mean ± standard deviation or median (r
Index, CVD: Cardiovascular Disease, TIA: Transient Ischemic Attack, CVA: Cerebrovas
BMI: Body Mass Index, eGRF: estimated Glomerular Filtration Rate, TC: Total Chole
NSAID: Non-Steroidal Anti-Inflammatory Drug.(IQR) or percentages, as appropriate. For comparisons
of variables with a normal distribution between two
groups, independent t-tests were used. The Pearson’s
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Basic demographics and disease characteristics
In total, 254 consecutive AS patients were included
(Table 1). The median age of the total AS population
was 42 years (IQR 35–51), and 170 patients (67%) were
male. Median disease duration was 7 years (IQR 2–14),
median CRP was 8 mg/l (IQR 3–25) and mean BASDAI
score was 5.9 ± 1.9. One-hundred-and-eighty patients
(71%) used NSAIDs. SBP and DPB levels did not signifi-
cantly differ between patients using NSAIDs (mean
SBP/DBP 126/80 mmHg) and not using NSAIDs (mean
SBP/DBP 131/82 mmHg), p = 0.4 and p = 0.9 respect-
ively. However, patients who used NSAIDs, as com-
pared to those who did not, significantly more often
used antihypertensive medication (26% vs. 9%, p =
0.003).Figure 1 Prevalences of hypertension (A), overweight (B) and hyperch
population in four different age categories. Legend: X-axis: age categor
general Dutch population.Prevalence of CV risk factors
Of 254 AS patients, eight patients (3%) had a history of
CVD and five patients (2%) were diagnosed with type 2
DM. One-hundred-and-nine patients (43%) smoked (45%
of the men and 38% of the women) compared to 27% of
the general Dutch population (30% of the men and 24%
of the women) p = 0.001. Mean BMI was 26.2 ± 4.6, 134
patients (53%) were overweight and 44 patients (17%)
were obese. Hypertension was present in 103 AS patients
(41%) versus 31% in the general population (p = 0.026).
Hypercholesterolemia was present in 30 patients (12%).
The results for hypertension, hypercholesterolemia and
overweight are displayed categorized by age and gender in
Figure 1. Compared to the general Dutch population, the
prevalences of hypertension and smoking are higher in AS
patients, the latter, however, only in AS males.olesterolemia (C) in AS patients compared to the general Dutch
ies, Y-axis: percentage, black: ankylosing spondylitis population, grey:
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Out of 254 patients, CV risk according to the Dutch
CV-RM guidelines could be assessed in 130 patients
(Table 2). One-hundred-and-eight patients were ex-
cluded as they were younger than 40 years, eight pa-
tients due to a history of CVD, and eight patients due to
lack of cholesterol or blood pressure data. According to
the Dutch CV-RM guidelines, nine patients (7%) were at
high CV risk, sixteen patients (12%) were at intermedi-
ate CV risk and 105 patients (81%) were at low CV risk.
When adding 15 years to the age of AS patients, CV risk
could be assessed in 231 AS patients (excluding seven
patients due to age below 40 years, eight patients due to
CVD history, eight patients due to lack of data). The
percentage of high CV risk patients increased to 26%
(Table 3). For the European and American guidelines the
percentage of patients at high CV risk was 22% and 29%,
respectively.CV risk management
According to the Dutch CV-RM guidelines, of the 130
screened AS patients, nine patients (7%) were not
treated at all while there was an indication for primary
CV risk prevention treatment and 22 patients (17%)
were inadequately treated, as treatment targets for blood
pressure or cholesterol levels were not reached (Table 2).
Of the eight patients with a history of CVD, all received
secondary prevention treatment, however, treatment tar-
gets were not reached in any of them.
In total, of the 138 AS assessed patients, 51 patients
had an indication for CV risk treatment of which 42 pa-
tients (82%) received some form of CV risk medication
(Figure 2). However, 39 (76%) of the 51 patients were
treated inadequately due to failure to reach treatment
targets for hypertension or hypercholesterolemia or due
to total lack of CV risk medication (Table 2). When the
modification factor (adding 15 years) was applied, under-
treatment of CV risk management was present in 44% of
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NA; not applicable N; number of patients, CV; cardiovascular * Patients who could n
pressure values.Discussion
In this observational cohort study we observed increased
rates of hypertension and smoking in patients with ac-
tive AS when compared to the general Dutch back-
ground population. This observation together with a
documented elevated CV risk in AS patients emphasizes
the need for optimal CV-RM. The majority of patients at
increased CV risk received treatment, but CV-RM re-
mains an important challenge for treating physicians, as
treatment targets were often not achieved.
Available studies of the prevalence of CV risk factors in
AS patients yield varying results. These differences could be
explained by the heterogeneity of study populations investi-
gated [4-6,19]. Given the close relationship between inflam-
mation, CV risk factors, and CV risk, we choose to assess
CV risk and its risk factors in AS patients with high disease
activity. In this selected population, we observed higher
prevalence rates of hypertension and smoking, but not
hypercholesterolemia and overweight. Inflammation may
deteriorate CV risk factors, but patients with active disease
may also experience more pain and physical stiffness, which
can induce physical inactivity, increasing the chance of
overweight and hypertension. The common use of NSAIDs
might also contribute to the increased prevalence of hyper-
tension. In fact, although the blood pressure was not signifi-
cantly different, anti-hypertensive agents were prescribed
significantly more in AS patients on NSAIDs.
The number of patients at high CV risk varied widely
depending on the CV risk algorithm that was used. Ac-
cording to the Dutch CV-RM guidelines, 7% of assessed
AS patients was at high CV risk, while 22% and 29%
were at high risk according to either the European or
American CV-RM guidelines. Overall, 5% of AS patients
was at high CV risk according to all three guidelines.
The large variation between the different CV-RM guide-
lines is remarkable. Several factors can explain this vari-
ation. First, the clinical outcomes on which the different
guidelines are based vary from 10-years CV risk to develop
a fatal atherosclerotic CV event (European CV-RM guide-




drugs N = 27
Both statin and






ot be included because of age <40 years or missing cholesterol/blood
Table 3 Cardiovascular risk according to Dutch, European and American guidelines
Total number of patients USA n = 130 EUR n = 130 DUTCH n = 130 DUTCH + 15 yr n = 231
High CV risk 29% (>7,5%) 22% (>5%) 7% (>20%) 26% (>20%)
Medium CV risk 13% (5–7,5%) 63% (1-5%) 12% (10-20%) 15% (10-20%)
Low CV risk 58% (<5,0%) 15% (<1%) 81% (<10%) 59% (<10%)
USA = American; EUR = European; N; number of patients, CV; cardiovascular. Between brackets the cutoff values for high, intermediate and low risk of a vascular
event for the appropriate cardiovascular risk management guidelines.
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lines), or to 10-years CV risk to develop a fatal or non-
fatal atherosclerotic event (Dutch CV-RM guidelines)
[7,8]. Second, all guidelines are applicable for different age
categories, i.e. Dutch for 40–70, European for 40–65, and
ACC/AHA for 40–79 years of age.
To date, it is recognized that systemic inflammation is an
important CV risk factor. However, none of the CV-RM
guidelines adjust for the inflammatory burden in AS pa-
tients, which could lead to underestimation of CV risk
[7,8]. The EULAR task force advised to use a multiplicationFigure 2 The identification of AS patients at increased CV risk. Legend
disease, n; number of patients. Cardiovascular risk treatment is according to
treated: not treated with statins and/or antihypertensive medication while
treatment not meeting treatment goals.factor of 1.5 to CV risk to adjust for the increased CV risk
in RA when patients have a disease duration >10 years,
rheumatoid factor or anti-cyclic citrullinated peptide posi-
tivity, or presence of extra-articular manifestations [12].
The Dutch CV-RM guidelines add 15 years to the age of all
RA patients to calculate CV risk, as is also applied in DM
patients [18]. Currently, due to lack of evidence, it is un-
known if, and if yes, what modification factor for CV risk
assessment in AS patients is most appropriate. To investi-
gate the impact of a modification factor for the increased
CV risk in AS patients, we used the same modification: AS; ankylosing spondylitis, CV; cardiovascular, CVD; cardiovascular
the Dutch cardiovascular risk management guideline. Inadequately
there was an indication for primary or secondary CV risk prevention
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adding 15 years to the age of the AS patients in this cohort,
the percentage of patients with high CV risk increases from
7% to 26%. Subsequently, undertreatment of this CV risk
increased from 28% to 44%. Future studies should be con-
ducted to investigate which CV risk stratification method
most accurately predicts CV risk in AS patients.
Since most patients with AS die from complications of
atherosclerosis, early identification and optimal CV-RM is
of utmost importance. It is reassuring that the awareness of
CV-RM was good, as the vast majority of AS patients at
risk for CV disease received treatment. However, it is
alarming to see that in 76% CV-RM was suboptimal, as
treatment targets were not reached. Moreover, in none of
AS patients needing secondary prevention of CV disease,
treatment targets were reached. Undertreatment of CV risk
(factors) can be caused by multiple factors. First, there
might be a lack of awareness of the increased CV risk in
AS patients in treating physicians. Second, CV-RM, includ-
ing CV risk screening, treatment, and follow-up, is time
consuming and lack of time to act on guidelines presents
an additional hurdle. Also, it is not clear who has responsi-
bility for CV-RM in AS patients, as this can be the primary
care physician, the treating rheumatologist, or both. The
number and complexity of available guidelines also impede
their implementation. Finally, since AS is often diagnosed
early in life, implementing a lifetime treatment with medi-
cation for CV risk (factors) is probably challenging for the
physician and is prone for non-compliance. These chal-
lenges need to be addressed to achieve a decrease in CV
morbidity and mortality in AS patients. It is therefore im-
portant that CV-RM in AS patients should be a joint effort
for the primary care physician and treating rheumatologist.
We should strive for increased awareness of CV risk and
need to identify and target high-risk individuals for primary
and secondary prevention.
A major strength of this study is the in-depth evaluation
of CV risk and CV risk factors. We estimated CV risk ac-
cording to various CV-RM assessment tools, thereby giving
an overview of the different outcomes on CV risk in this
AS population. However, only AS patients with active dis-
ease and from a single rheumatology centre were included
which hampers generalizability. Finally, due to the retro-
spective design of this study, there was no data available on
the reasons why CV risk treatment was suboptimal. This
complicates further evaluation of CV-RM implementation,
as it is possible that increased CV risk is acknowledged but
treatment is not initiated because of side effects, comorbid-
ity, or patients’ non-adherence.
Conclusions
In conclusion, this study shows that the prevalence of
hypertension and smoking is increased in AS patients
with active disease. Also, AS patients at increased CVrisk received medication, but treatment targets were often
not achieved. Our data illustrate the need for programs to
improve the quality of CV-RM in AS.
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